London-listed Amryt Pharma (AIM:AMYT) will showcase its research on Epidermolysis Bullosa (EB), a rare and untreated skin disorder at an inaugural EB World Congress held in London later this month.
Amryt’s EB research programme aims at relieving symptoms and finding a possible cure for the genetic skin disorder for which there is currently no approved treatment.
The international biopharmaceutical company will offer information on an investigational treatment for the condition, AP101, on 21 January 2020 at the EB World Congress 2020 (EB2020).
"EB2020 presents an ideal opportunity for us to share our ideas, meet new partners and galvanise our shared vision to make a real difference for people living with EB,” said Dr Joe Wiley, CEO of Amryt.
The conference, which is taking place from 19-23 January, will offer value to EB professionals, covering strategy approaches crossing research, regulatory and funding.
“Collaborating with industry partners, sponsors such as Amryt, healthcare professionals, and the EB Community gives us hope that people living with EB will have a much brighter future,” said Congress Director, Caroline Collins.
Amryt scientist, Dr Lara Cutlar, has also been invited to present a talk on non-viral gene therapy delivery mechanisms on the same day, the company explained.
On 22 January, Dr Mark Sumeray, Amryt’s Chief Medical Officer will present an outline of the research programme as part of the conference.
The group have spent over three years supporting research efforts within the EB community as well as attracting “significant investment” to their own programme, Wiley explained.
Amryt is currently conducting a phase 3 trial in EB, the EASE trial, at 55 sites across 27 countries — results are expected later this year.
Follow News & Updates from Amryt Pharma here: